Product Images Brevibloc

BREVIBLOC is an intravenous medication containing esmolol hydrochloride, available in a ready-to-use vial of 100mg/10ml. The medication is free of preservatives and should be discarded following use. Avoid exposing the medication to alkalies, and do not use it if discolored or precipitate is present. Keep out of reach of children. The medication should be stored within the temperature range of 59-86F. The item and lot numbers, as well as prescribing information, are printed on the packaging. It is packaged by Henry Schein, Inc. The GTIN, SER, LOT, and EXPIRATION are available although their values are not readable in the text.*

This is a table indicating step-wise dosing instructions. It suggests optional loading doses of 500 mcg per kg over 1 minute, followed by 50 mcg per kg per minute for 4 minutes, with an option to increase the dose to 100 mcg per kg per min or 150 mcg per kg per min for 4 minutes. In case of need, the dose may increase to 200 mcg per kg per min.*

This is a table with three different presentations of BREVIBLOC Injection, a medication containing Esmolol Hydrochloride, used to control high blood pressure or irregular heartbeats (arrhythmias). The three presentations are: BREVIBLOC PREMIXED Injection with a total dose of 2500 mg / 250 mL and concentration of 10 mg/mL, BREVIBLOC DOUBLE STRENGTH PREMIXED Injection with a total dose of 2000 mg /100 mL and concentration of 20 mg/mL, and BREVIBLOC Injection with a total dose of 100 mg /10 mL and concentration of 10 mg/mL. BREVIBLOC PREMIXED and DOUBLE STRENGTH PREMIXED are packaged in bags of 250 mL and 100 mL, respectively, while BREVIBLOC Injection is packaged in a 10 mL vial.*

This is a table showing the clinical trial adverse reactions for a medication called BREVIBLOC (Esmolol Hydrochloride). The table shows the preferred MedDRA terms for each system organ class (SOC) and the frequency of adverse reactions that occurred in more than 3% of patients. The adverse reactions observed include hypotension (asymptomatic and symptomatic), infusion site reactions, nausea, dizziness, and somnolence. According to the table, hypotension resolved during infusion in 63% of patients, and in 80% of the remaining patients, hypotension resolved within 30 minutes following discontinuation of infusion.*

Table 4 BREVIBLOC Injection Formulations showing the strength and ingredients present in three different types of injections: BREVIBLOC PREMIXED Injection, BREVIBLOC DOUBLE PREMIXED Injection, and BREVIBLOC Injection. All three formulations contain Esmolol Hydrochloride, Sodium Chloride, USP, and Sodium Acetate Trihydrate, USP. The BREVIBLOC PREMIXED Injection contains Glacial Acetic Acid, USP, and has a strength of 10mg/mL. The BREVIBLOC DOUBLE PREMIXED Injection contains Glacial Acetic Acid, USP, and has a strength of 20mg/mL. The BREVIBLOC Injection contains Glacial Acetic Acid, USP, Hydrochloric Acid / Sodium Hydroxide to adjust pH and has a strength of 10mg/mL. The pH level of all the injections is adjusted to 4.5-5.5.*